ArticleJournal of the science of food and agriculture2026
Egg yolk hydrolysate shows moderate impact on osteoporosis in ovariectomized rats.
Article in Journal of the science of food and agriculture, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study investigated the protective effect of egg yolk hydrolysate (FC) on osteoporosis in ovariectomized (OVX) rats, a well-established model of postmenopausal bone loss. OVX rats were fed diets supplemented with 0.2% or 1% FC for 13 weeks. The regulatory effects were evaluated by measuring bone mineral density (BMD) and microarchitecture using computed tomography, analyzing serum bone remodeling biomarkers, and examining osteoclast differentiation and resorption activity in isolated bone marrow cells. Western blotting was used to evaluate the expression of key osteoclastogenic proteins.
resultsFC 1% supplementation significantly improved trabecular BMD and percentage bone volume in OVX rats. Treatment with FC 1% also significantly increased serum osteocalcin levels (P = 0.028). Furthermore, FC 1% significantly reduced osteoclast differentiation (decreased tartrate-resistant acid phosphatase-positive area by approximately 49%, P < 0.05) and bone resorption activity. At the molecular level, FC 1% significantly decreased cellular Fos (c-Fos) expression, whereas other osteoclastogenic proteins, including nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), cathepsin K and matrix metalloproteinase 9 (MMP-9), showed non-significant downward trends.
conclusionThese findings indicate that FC exerts moderate protective effects against bone loss in OVX rats by simultaneously suppressing osteoclast activity and enhancing bone formation. These results support the potential of egg yolk hydrolysate as a functional food ingredient for osteoporosis management, particularly in postmenopausal women. Further investigations are needed to fully understand the underlying mechanisms and assess long-term efficacy. © 2026 The Author(s). Journal of the Science of Food and Agriculture published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.